Last reviewed · How we verify
Switching to Tenofovir Alafenamide — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Switching to Tenofovir Alafenamide (Switching to Tenofovir Alafenamide) — Mahidol University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Switching to Tenofovir Alafenamide TARGET | Switching to Tenofovir Alafenamide | Mahidol University | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Switching to Tenofovir Alafenamide CI watch — RSS
- Switching to Tenofovir Alafenamide CI watch — Atom
- Switching to Tenofovir Alafenamide CI watch — JSON
- Switching to Tenofovir Alafenamide alone — RSS
Cite this brief
Drug Landscape (2026). Switching to Tenofovir Alafenamide — Competitive Intelligence Brief. https://druglandscape.com/ci/switching-to-tenofovir-alafenamide. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab